Table 2.
Clinical and laboratory characteristics of the juvenile rheumatoid arthritis (JRA) patients characterised
| Sample | Clinical features and rheumatoid factor status |
Age Onset |
Age History |
Fibrinogen ICs (O.D.) | Anti-cit. fibrinogen IgG (O.D.) |
anti-CCPa (IU/mL) |
RFb (IU/mL) |
| JRA 1 | Polyarthritis, RF- | 2 | 2 | 0.18 | 0.11 | 21.3 | 11.7 |
| JRA 4 | Polyarthritis, RF+ | 13 | 0.77 | 1.25 | 841.1 | 127.6 | |
| JRA 8 | Polyarthritis, RF+ | 3 | 16 | 0.53 | 0.43 | 483.2 | 262.6 |
| JRA 13 | Polyarthritis, RF+ | 13 | 13 | 0.54 | 1.45 | 255.4 | 274.7 |
| JRA 17 | Systemic arthritis | 0.15 | 0.10 | 24.8 | 24.9 | ||
| JRA 22 | Polyarthritis, RF- | 15 | 15 | 0.13 | 0.09 | 22.7 | 27.1 |
| JRA 27 | Polyarthritis, RF- | 1 | 2 | 0.10 | 0.08 | 20.3 | 7.6 |
| JRA 31 | Persistent oligoarthritis | 0.16 | 0.13 | 21.5 | 7.3 | ||
| JRA 32 | Polyarthritis, RF- | 5 | 5 | 0.12 | 0.37 | 26.7 | 6.3 |
| JRA 41 | Enthesitis-related arthritis | 13 | 14 | 0.14 | 0.08 | 20.8 | 13.1 |
| JRA 42 | Systemic arthritis | 12 | 12 | 0.17 | 0.08 | 21.8 | 7.1 |
| JRA 44 | Polyarthritis, RF- | 9 | 9 | 0.19 | 0.09 | 20.9 | 10.1 |
| JRA 49 | Polyarthritis, RF+ | 9 | 1.72 | 0.74 | 1275.4 | 295.2 | |
| JRA 51 | Systemic arthritis | 5 | 5 | 0.14 | 0.09 | 21.4 | 7.6 |
| JRA 71 | Polyarthritis, RF+ | 10 | 0.19 | 0.21 | 360.9 | 186.1 | |
| JRA 79 | Polyarthritis, RF- | 4 | 4 | 0.20 | 0.10 | 22.1 | 11.7 |
| JRA 88 | Polyarthritis, RF+ | 11 | 11 | 0.51 | 0.35 | 287.0 | 236.4 |
| JRA 106 | Extended oligoarthrits | 1 | 3 | 0.15 | 0.12 | 22.0 | 10.0 |
| JRA 110 | Persistent oligoarthritis | 0.15 | 0.10 | 24.9 | 14.6 | ||
| JRA 112 | Enthesitis related arthritis | 0.14 | 0.12 | 22.5 | 15.9 |
a,bMeasured with commercial kits. JRA, juvenile rheumatoid arthritis; IC, immune complex; CCP, cyclic-citrullinated peptides; RF, rheumatoid factor; O.D., optical density